Site Editor

Gregory J. Riely, MD, PhD

Advertisement

Advertisement

News

Real-World Prognostic Impact of Tumor Suppressor Gene Alterations in Advanced NSCLC

News

Tumor Immune Dynamics With Neoadjuvant Chemoimmunotherapy in Locally Advanced NSCLC

Medical Literature

AI Model Predicts Rare Gene Mutations in Patients With Lung Adenocarcinoma

News

Pembrolizumab and Comedications for Advanced NSCLC

News

Pembrolizumab and Comedications for Advanced NSCLC

Medical Literature

Preventing Skin Toxicities After Treatment With Nivolumab + Ipilimumab

Medical Literature

Steroid Use Could Impact Checkpoint Inhibitor Efficacy in NSCLC

Marisa Bittoni, PhD, on Vaping, Smoking, and Lung Cancer

Melina Marmarelis, MD, on Combining Pembrolizumab and Itacitinib in PD-L1–Positive NSCLC

View More

Advertisement

JNCCN Spotlights

Repotrectinib for ROS1-Positive NSCLC

(NEW Update) Nivolumab in NSCLC

(NEW Update) Pembrolizumab in NSCLC

Dabrafenib + Trametinib (Tafinlar + Mekinist)

(UPDATE) Nivolumab (Opdivo) in NSCLC

Sotorasib

View More

More

News

Tumor Immune Dynamics With Neoadjuvant Chemoimmunotherapy in Locally Advanced NSCLC

CheckMate 816: Overall Survival With Nivolumab Plus Chemotherapy in Resectable NSCLC

Increased Risks of Lung Cancer Among Those With Higher Genetic Sensitivity to Stress

Real-World Prognostic Impact of Tumor Suppressor Gene Alterations in Advanced NSCLC

Introduction to Myelofibrosis and Highlights from the 2025 ASCO Annual Meeting

Iruplinalkib Showed Favorable Activity Against G1202R Resistance Mutation in NSCLC

Pembrolizumab and Comedications for Advanced NSCLC

View More

Advertisement

Published

Medical Literature

The Impact of Family Cancer History on Prognosis in Patients With NSCLC

Solid Lung Nodules Found in Northern European Nonsmoking Cohort: Much to Be Learned

Does Where Patients Live Affect Their Chances of Surviving Lung Cancer?

TROPION-Lung01: Dato-DXd vs Docetaxel in Advanced Lung Cancer

View More

Ongoing

CE Activities

Improving Lung Cancer Care Through Understanding the Patient Experience

Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy

Implications of Recent Data Sets for the Current and Future Management of Lung Cancer

Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

View More

Available

Clinical Trials

LATIFY: Ceralasertib Plus Durvalumab vs Docetaxel in NSCLC Whose Disease Progressed on or After Prior Anti–PD(L)1 Therapy and Platinum-Based Chemotherapy

An Open-Label, Randomized, Multicenter, Phase III Study of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations

Study of Avutometinib (VS-6766) Plus Adagrasib in KRAS G12C NSCLC Patients

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in NSCLC

View More

Resources

For Your Patients

The American Lung Association

Bonnie J. Addario Lung Cancer Foundation

Caring Ambassadors Program

Dusty Joy Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2025 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.